Skip to main content

Table 1 SAX patients characteristics

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

 

N = 148

%

Median age years (range)

62

(35–85)

Age

 < 75

126

85%

 ≥ 75

22

15%

Gender

 Male

75

50.7%

 Female

73

49.3%

ECOG PS

 0

82

55.4%

 1

61

41.3%

 2

5

3.3%

Nephrectomy

 Yes

134

90.5%

 No

14

9.5%

MOTZER score

 Poor

17

11.5%

 Intermediate

90

60.8%

 Favorable

41

27.7%

Heng score

 Poor

23

15.5%

 Intermediate

89

60.1%

 Favorable

36

24.3%

Principal sites of disease

 Lung

84

56.8%

 Lymph node

55

37.2%

 Bone

39

26.4%

 Liver

33

22.3%

 Adrenal glands

10

6.8%

 Brain

9

6.1%

 Local recurrence

8

5.4%

 Pancreas

7

4.7%

 Peritoneum

6

4.1%

 Contralateral kidney

5

3.4%

 Skin

3

2%

 Spleen

2

1.4%